

1-12-02

RECEIVED  
FEB 05 2002

TECH CENTER 1600/2900  
PTO/SB/21 (6-99)  
+ 1

Please type a plus sign (+) inside this box → ☐

Approved for use through 09/30/2000 OMB 0651-0031  
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

<b>TRANSMITTAL FORM</b> <i>(to be used for all correspondence after initial filing)</i>	Application Number	09/966,781	
	Filing Date	09/28/2001	
	First Named Inventor	Patricia Soulard	
	Group Art Unit	1645	
	Examiner Name		
Total Number of Pages in This Submission		Attorney Docket Number	A0000281-66-MG

ENCLOSURES (check all that apply)		
<input type="checkbox"/> Fee Transmittal Form <input type="checkbox"/> Fee Attached <input type="checkbox"/> Amendment / Response <input type="checkbox"/> After Final <input type="checkbox"/> Affidavits/declaration(s) <input type="checkbox"/> Extension of Time Request <input type="checkbox"/> Express Abandonment Request <input checked="" type="checkbox"/> Information Disclosure Statement <input type="checkbox"/> Certified Copy of Priority Document(s) <input type="checkbox"/> Response to Missing Parts/Incomplete Application <input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53	<input type="checkbox"/> Assignment Papers (for an Application) <input type="checkbox"/> Drawing(s) <input type="checkbox"/> Licensing-related Papers <input type="checkbox"/> Petition Routing Slip (PTO/SB/69) and Accompanying Petition <input type="checkbox"/> Petition to Convert to a Provisional Application <input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address <input type="checkbox"/> Terminal Disclaimer <input type="checkbox"/> Small Entity Statement <input type="checkbox"/> Request for Refund	<input type="checkbox"/> After Allowance Communication to Group <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences <input type="checkbox"/> Appeal Communication to Group (Appeal Notice, Brief, Reply Brief) <input type="checkbox"/> Proprietary Information <input type="checkbox"/> Status Letter <input checked="" type="checkbox"/> Additional Enclosure(s) (please identify below): Return Postcard Certificate of Express Mail
Remarks		

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT	
Firm or Individual name	Mehdi Ganjeizadeh
Signature	
Date	1/16/02

CERTIFICATE OF MAILING			
I hereby certify that this correspondence is being deposited with the United States Postal Service as <u>first class mail</u> in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231 on this date: <u>Jan 16 2002</u>			
Typed or printed name	Linda A. Zerby	Date	<u>Jan 16 2002</u>
Signature			

⊕ Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.


USSN 09/966 781  
EXPRESS MAIL NO. EF3/8128626US  
PD-A0000281-66-MG

RECEIVED

USSN 09/466 781  
EXPRESS MAIL NO. EF378128626US  
PD-A0000281 66-MG

FEB 05 2002

TECH CENTER 1600/2900

<b>CERTIFICATE OF MAILING BY "EXPRESS MAIL" (37 CFR 1.10)</b> Applicant(s): Patricia Soudard			Docket No. A0000281-66-MG	
Serial No. 09 966,781	Filing Date 28-Sep-2001	Examiner	Group A 1645	
Invention: POLYPEPTIDES EXHIBITING PDE7 ACTIVITY AND THEIR USE FOR SELECTING COMPOUNDS WHICH INHIBIT PDE 7 ENZYME ACTIVITY				
<p>I hereby certify that this <u>Information Disclosure Statement</u> <small>(Identify type of correspondence)</small></p> <p>Is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 in an envelope addressed to: The Assistant Commissioner for Patents, Washington, D.C. 20231</p> <p>on <u>January 16, 2002</u> <small>(Date)</small></p> <div style="text-align: right;"> <p><u>Linda A. Zerby</u> <small>(Typed or Printed Name of Person Mailing Correspondence)</small></p> <p><u></u> <small>(Signature of Person Mailing Correspondence)</small></p> <p><u>EF378128626US</u> <small>("Express Mail" Mailing Label Number)</small></p> </div> <p style="text-align: center;"><b>Note: Each paper must have its own certificate of mailing</b></p>				



Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office, U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

**Complete if Known**

<b>Application Number</b>	09:966,781
<b>Filing Date</b>	September 28, 2001
<b>First Named Inventor</b>	Patricia Soulard
Group Art Unit	1645
<b>Examiner Name</b>	
<b>Attorney Docket Number</b>	A0000281-66-MG

(use as many sheets as necessary)

Sheet	1	of	3
-------	---	----	---

U.S. PATENT DOCUMENTS

[illegible]

## FOREIGN PATENT DOCUMENTS

[illegible]

Examiner  
Signature

Date	
Considered	

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST 3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.


**Burden Hour Statement:** This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231.

**DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:** Assistant Commissioner for Patents, Washington, DC 20231.

USSN 09/966 781 PD-A0000281 66-MC  
EXPRESS MAIL NO. EF378128626US

RECEIVED

Please type a plus sign (+) inside this box → ☐



PTO/SB/08B (08-00)  
Approved for use through 10/31/2002 OMB 0651-0031

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 2 of 3

### Complete if Known

Application Number	09/966,781
Filing Date	September 28, 2001
First Named Inventor	Patricia Soulard
Group Art Unit	1645
Examiner Name	
Attorney Docket Number	A0000281-66-MG

### OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS

Examiner Initials <sup>1</sup>	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS); title of the article (when appropriate); title of the item (book, magazine, journal, serial, symposium, catalog, etc.); date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
		J.A. BEAVO, Physiol. Rev., 1995, pp 725-748, Vol. 75	
		T.L. FINK, et al., "Expression of an Active, Monomeric Catalytic Domain of the cGMP-binding cGMP-specific Phosphodiesterase (PDE5)", J. Biol. Chem., 12/3/1999, pp 34,613-34,620, Vol. 274, No. 49	
		J LIM, et al., "Activation of the cAMP-specific Phosphodiesterase PDE4D3 by Phosphorylation" J. Biol. Chem., 7/9/1999, pp 29677-19685, Vol. 274, No. 28	
		S.L.C. JIN, et al. "Characterization of the Structure of a Low Km, Rolipram-sensitive cAMP Phosphodiesterase", J. Biol. Chem., 9/15/1992, pp 18929-18939, Vol. 267, No. 26	
		T. KOVALA, et al., "Recombinant Expression of a Type IV, cAMP-Specific Phosphodiesterase: Characterization and Structure-Function Studies of Deletion Mutants", Biochem., 1997, pp 2968-2976, Vol. 36	
		T. MICHAELI, et al., "Isolation and Characterization of a Previously Undetected Human cAMP Phosphodiesterase by Complementation of CAMP Phosphodiesterase-deficient Saccharomyces cerevisiae", J. Biol. Chem., 6/15/1993, pp 12925-12932, Vol. 268, No. 17	
		W.K. SONNENBURG, et al., "Identification of Inhibitory and Calmodulin-binding Domains of the PDE1A1 and PDE1A2 Calmodulin-stimulated Cyclic Nucleotide Phosphodiesterases", J. Biol. Chem., 12/29/1995, pp 30989-31000, Vol. 270, No. 52	
		Y. KENAN, et al., "Functions of the N-terminal Region of Cyclic Nucleotide Phosphodiesterase 3 (PDE 3) Isoforms", J. Biol. Chem., 4/21/2000, pp 12331-12338, Vol. 275, No. 16	
		WOLFGANG BAEHR, et al. "Isolation and Characterization of cGMP Phosphodiesterase from Bovine Rod Outer Segments", J. Biol. Chem., 11/25/1979, pp 11669-11677, Vol. 254, No. 22	
		J. A. BEAVO, et al., "Hydrolysis of Cyclic Guanosine and Adenosine 3',5'-Monophosphates by Rat and Bovine Tissues", J. Biol. Chem., 11/10/1970, pp 5649-5655, Vol. 245, No. 21	
		TIMOTHY J. BLOOM, et al., "Identification and Tissue-specific Expression of PDE7 Phosphodiesterase Splice Variants", Proc. Natl. Acad. Sci. USA, 11/1996, pp 14188-14192, Vol. 93	

Examiner  
Signature

Date  
Considered

\*EXAMINER Initial if reference considered, whether or not citation is in conformance with MPEP 609 Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached


Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

RECEIVED

FEB 05 2002

Please type a plus sign (+) inside this box → ☐

Under the Paperwork Reduction Act of 1995, no person is required to respond to a collection of information unless it contains a valid OMB control number.



PTO/SB/08B (08-00)  
Approved for use through 10/31/2002 OMB 0651-0031

U. S. Patent and Trademark Office U. S. DEPARTMENT OF COMMERCE

TECH CENTER 160012900

JAN 05 2002

RECEIVED

<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)		<b>Complete if Known</b>			
		Application Number	09,966,781		
		Filing Date	September 28, 2001		
		First Named Inventor	Patricia Soulard		
		Group Art Unit	1645		
		Examiner Name			
Sheet	3	of	3	Attorney Docket Number	A0000281-66-MG

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
		BERNARD K. K. FUNG, et al., "Subunit Stoichiometry of Retinal Rod cGMP Phosphodiesterase", Biochem., 1990, pp 2657-2664, Vol. 29	
		CLARE GARDNER, et al., "Cloning and Characterization of the Human and Mouse PDE7B, a Novel cAMP-Specific Cyclic Nucleotide Phosphodiesterase", Biochem. Biophys. Res. Commun., 2000, pp 186-192, Vol. 272	
		PING HAN, et al., "Alternative Splicing of the High Affinity cAMP-Specific Phosphodiesterase (PDE7A) mRNA in Human Skeletal Muscle and Heart, J. Biol. Chem., 6/27/1997, pp 16152-16157, Vol. 272, No. 26	
		RALF HOFFMANN, et al., "Differential Distribution of Rat PDE-7 mRNA in Embryonic and Adult Rat Brain, Cell Biochem. Biophys., 1998, pp 103-113, Vol. 28	
		MICHIO ICHIMURA, et al., "A new Cyclic Nucleotide Phosphodiesterase Isozyme Expressed in the T-Lymphocyte Cell Lines", Biochem. Biophys. Res Commun., 6/30/1993, Vol. 193, No. 3	
		CAROLYN J. SMITH, et al., "Hormone-sensitive Cyclic GMP-inhibited Cyclic AMP Phosphodiesterase in Rat Adipocytes", J. Biol. Chem., 7/15/1991, pp 13385-13390, Vol. 266, No. 20	
		THEODORE J. TORPHY, et al., "Biochemical Characterization and Cellular Regulation of Phosphodiesterase IV", New Drugs in Allergy and Asthma, 1993, pp 51-71, Agents & Actions Supplement Vol. 43	
		Genbank Accession No: U77880; Rattus norvegicus GI:1916748; 9/28/2001	
		Genbank Accession No: AJ251860 Homo sapiens mRNA GI:8216982; 5/24/200	
		Genbank Accession No: L12052 Homo sapiens cAMP GI:179892; 7/22/1999	
		Genbank Accession No: U68171 Mus musculus cycl GI:1549394; 9/18/1996	
		Genbank Accession No: U67932 Homo sapiens cAMP GI:2306763; 7/22/1999	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.